The investigational agents shown below are not approved anywhere globally, and the safety and efficacy of these agents are not known. This information is intended as scientific information for Healthcare Professionals only.
Gilead Clinical Trials
Gilead HIV Pipeline
Gilead’s research and development program is focused on what’s next. Shown here is our current pipeline and phases of development.
Ongoing Phase 2/3 Clinical Trials for HIV Treatment: CAPELLA and CALIBRATE
Two studies (CAPELLA and CALIBRATE) are currently enrolling participants to evaluate the efficacy and safety of investigational lenacapavir (LEN), a novel capsid inhibitor, for the potential treatment of HIV. LEN is administered as a long-acting subcutaneous injection every 6 months in these studies.
- CAPELLA is studying LEN as an add-on to a failing regimen in heavily treatment-experienced people living with HIV (PLWH) with multidrug resistance
- CALIBRATE is studying LEN plus other oral antiretrovirals in treatment-naïve PLWH
Additional information on active sites for these studies can be found on clinicaltrials.gov: